10 Best Cancer Stocks to Invest in for Long-Term Gains

3. argenx SE (NASDAQ:ARGX)

Number of Hedge Fund Holders: 47

Total 5-Year Return: 333.46%

The third-ranking stock on our list of the best cancer stocks is argenx SE (NASDAQ:ARGX). It is a global biopharma company specializing in antibody-based therapies for autoimmune diseases and cancer. Its proprietary SIMPLE Antibody platform enables the development of highly effective, differentiated antibodies. The company’s lead product, VYVGART, is an FcRn antagonist and targets the neonatal Fc receptor to reduce harmful antibodies and is approved for conditions like myasthenia gravis and CIDP.

argenx SE (NASDAQ:ARGX) reported $737 million in product net sales for the fourth quarter of 2024 and $2.2 billion for the entire year. Its net profit was $774 million in Q4 and $833 million in 2024, while total operating income was $761 million in Q4 and $2.3 billion for the year. The business had a healthy $3.4 billion cash position after the year.

A 98% year-over-year increase in product net sales allowed argenx SE (NASDAQ:ARGX) to reach over 10,000 patients worldwide across three approved indications. VYVGART, its flagship medication, is being widely used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and has significantly impacted the therapy of generalized myasthenia gravis (gMG).

With ambitious targets for the future, the corporation is moving forward with its Vision 2030 strategy: treating 50,000 patients, obtaining 10 labeled indications, and advancing five pipeline prospects to Phase 3. With 20 ongoing clinical trials, including 10 Phase 3 and 10 Phase 2 investigations, the company is well-positioned for long-term success.

With anticipated R&D and SG&A expenditures of $2.5 billion, argenx SE (NASDAQ:ARGX) anticipates 2025 to be its first profitable year, demonstrating its dedication to innovation. With a favorable CHMP recommendation for the VYVGART pre-filled syringe in the EU and an FDA decision anticipated by April 10, 2025, the regulatory process is still ongoing and might increase treatment accessibility and market reach.